Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.42 |
| ▸ | KDM5A | P29375 | 5/20 | 0.42 |
| ▸ | KDM4A | O75164 | 2/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1404091 | 0.92 | SMN1; SMN2 (0.55) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL717534 | 0.92 | SMN1; SMN2 (0.55) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL1403908 | 0.90 | LMNA (0.57) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL1241235 | 0.90 | SMN1; SMN2 (0.52) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL4880552 | 0.90 | LMNA (0.57) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL23016786 | 0.90 | LMNA (0.57) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL7626625 | 0.90 | LMNA (0.57) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL20756484 | 0.90 | LMNA (0.57) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL1403868 | 0.90 | LMNA (0.57) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL10398804 | 0.90 | LMNA (0.57) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399409-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF SE (DE) | 2012-10-31 | — | — | EP | claimed |
| CN-100349854-C | Method for producing (meth) acrylic acid esters | BASF AG (DE) | 2007-11-21 | — | — | CN | claimed |
| CN-100349851-C | Method for producing acrylic acid esters | BASF AG (DE) | 2007-11-21 | — | — | CN | claimed |
| US-7268251-B2 | Method for producing (meth) acrylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2007-09-11 | — | — | US | claimed |
| US-7026503-B2 | Method for producing (meth)acrylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-11 | — | — | US | claimed |
| EP-1399408-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AG (DE) | 2006-03-22 | — | — | EP | claimed |
| WO-2023250427-A2 | FORMULATIONS FOR MODULATING MYC EXPRESSION | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023250375-A1 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | ORNA THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023056033-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | ORNA THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2022261490-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2021226597-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226129-A1 | SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF | NEURALEXO, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-0668271-B1 | Process for the preparation of isocyanurate-group containing polyisocyanates | BASF AG (DE) | 2002-01-16 | — | — | EP | disclosed |
| EP-0838508-B1 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORP (JP) | 2001-08-29 | — | — | EP | disclosed |
| US-5871572-A | COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID | SEIKO EPSON CORPORATION (JP) | 1999-02-16 | — | — | US | disclosed |
| EP-0838508-A2 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORPORATION (JP) | 1998-04-29 | — | — | EP | disclosed |
| US-5489663-A | TRIMERIZING ALIPHATIC AND/OR CYCLOALIPHATIC DIISOCYANATES USING TETRAALKYLAMMONIUM ALKYL CARBONATE OR MIXTURES WITH QUATERNARY AMMONIOALKYL CARBONATE CATALYSTS, DEACTIVATING CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-06 | — | — | US | disclosed |
| EP-0400435-B1 | Carbonic half-ester of betaine structure | BASF AG (DE) | 1994-04-13 | — | — | EP | disclosed |
| EP-0400435-A2 | Carbonic half-ester of betaine structure | BASF Aktiengesellschaft (DE) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | ALDH1A1 4315/4885SMN1; SMN2 2768/4885LMNA 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.